Bortezomib will enhance the degree or outcome of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Increased flibanserin adverse results may perhaps arise if coadministered with various weak CYP3A4 inhibitors. Screen for hepatitis B virus in all cancer people commencing systemic treatment. Determine more details on hepatitis B virus https://hankh554vhs8.wonderkingwiki.com/user